A 1-Month-Old Baby with Osteogenesis Imperfecta: A Case Report

Andry Juliansen, Anne Meilyn, Lisa Rehinda Tampake

Abstract


Osteogenesis imperfecta (OI) is a connective tissue formation disorder that is generally characterized by bone fragility, osteopenia, blue sclera, dentinogenesis imperfecta (DI), and hearing loss. This disease occurs due to changes in collagen type 1 that form the basis of bone formation so that bones tend to be thinner and smaller. The bones become weak and easily cracked. OI has been classified by type according to the system based on the mode of inheritance, clinical features, and information from the X-ray. There are four types of osteogenesis imperfecta, namely Type I, Type II, Type III, and Type IV. Health problems are often seen in children and adults who have OI include: short stature, weak tissues, fragile skin, muscle weakness, and loose joints, bleeding, easy bruising, frequent nosebleeds, and tiny amounts of heavy bleeding from the wound, impaired loss of hearing can begin in childhood and affects approximately 50 % of adults, breathing problems, a higher incidence of asthma plus risk for other lung problems, spinal curvature.


Keywords


congenital abnormalities; osteogenesis imperfecta; pediatrics



DOI: http://dx.doi.org/10.19166/med.v9i2.4706

Full Text:

PDF

References


1. Al-Agha AE, Hayatalhazmi RS. Osteoporosis treatment with zoledronic acid in the pediatric population at a university hospital in Western Saudi Arabia. Saudi Med J. 2015; 36: 1312-1318. https://doi.org/10.15537/smj.2015.11.12590

2. Alharbi, SA. 2016. A systematic overview of osteogenesis imperfecta. Mol Biol. 2016; 5: 1-9. http://doi.org/10.4172/2168-9547.1000150

3. Byers PH, Krakow D, Nunes ME, Pepin M. Genentics in Medicine. 2006; 8: 383-388. https://doi.org/10.1097/01.gim.0000223557.54670.aa

4. Dijk VFS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature, and severity assessment. Am J Med Genet Part A. 2014; 164A: 1470-1481.https://doi.org/10.1002/ajmg.a.36545

5. Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, dkk. A controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gain but not a short-term functional improvement. J Bone and Mineral. 2005; 20: 977-986. https://doi.org/10.1359/JBMR.050109

6. Lindahl K, Kindmark A, Rubin CJ, Malmgren B, Grigelioniene G, Söderhäll S. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with pamidronate. Bone. 2016; 87: 11-18. https://doi.org/10.1016/j.bone.2016.02.015

7. Marzuki NS, Batubara JRL. Osteogenesis Imperfecta. In: Batubara JRL, Tridjaja B, Pulungan A, Editors. Buku Ajar Endokrinologi Anak. 2nd ed. In Press.

8. Rijks EBG, Bongers BC, Vlemmix MJG, Boot AM, van Dijk ATH, Sakkers RJB, dkk. Efficacy and safety of bisphosphonate therapy in children with osteogenesis imperfecta: systematic review, hormone research in pediatrics. Horm Res Paediatr. 2015; 84: 26-42. https://doi.org/10.1159/000381713

9. Sánchez-Sánchez LM, Cabrera-Pedroza AU, Palacios-Saucedo G, de la FuenteCortez B Zoledronic acid (zoledronate) in children with osteogenesis imperfecta (OI). Gac Med Mex. 2015; 151: 152-156.

10. Starr RS, Roberts TT, Fischer PR. Osteogenesis Imperfecta: Primary Care. Ped in Review. 2010; 31: e54-e64. https://doi.org/10.1542/pir.31-8-e54

11. van Dijk FS, Byers PH, Dalgleish R, Malfait F, Maugeri A, Rohrbach M, dkk. Best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. European Journal of Human Genetics. 2012; 20: 11-19. https://doi.org/10.1038/ejhg.2011.141

12. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics. 2003; 111: 1030-6. https://doi.org/10.1542/peds.111.5.1030


Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Andry Juliansen, Anne Meilyn, Lisa Rehinda Tampake

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

 

Creative Commons License

MEDICINUS is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Copyright © Fakultas Kedokteran | Universitas Pelita Harapan | Lippo Karawaci, Tangerang, Indonesia, 15811 . All rights reserved. p-ISSN 1978-3094 | e-ISSN 2622-6995